Masimo/$MASI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Masimo
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Ticker
$MASI
Sector
Primary listing
Employees
3,600
Headquarters
Website
Masimo Metrics
BasicAdvanced
$8B
-
-$8.54
1.23
-
Price and volume
Market cap
$8B
Beta
1.23
52-week high
$194.88
52-week low
$111.03
Average daily volume
789K
Financial strength
Current ratio
2.145
Quick ratio
0.848
Long term debt to equity
59.388
Total debt to equity
61.584
Interest coverage (TTM)
2.02%
Profitability
EBITDA (TTM)
153.8
Gross margin (TTM)
49.11%
Net profit margin (TTM)
-21.32%
Operating margin (TTM)
3.62%
Effective tax rate (TTM)
-6.18%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
1.84%
Return on equity (TTM)
-22.37%
Valuation
Price to revenue (TTM)
3.683
Price to book
7.68
Price to tangible book (TTM)
9.06
Price to free cash flow (TTM)
59.064
Free cash flow yield (TTM)
1.69%
Free cash flow per share (TTM)
2.496
Growth
Revenue change (TTM)
25.86%
Earnings per share change (TTM)
-678.78%
3-year revenue growth (CAGR)
12.70%
10-year revenue growth (CAGR)
13.39%
3-year earnings per share growth (CAGR)
36.69%
10-year earnings per share growth (CAGR)
19.72%
What the Analysts think about Masimo
Analyst ratings (Buy, Hold, Sell) for Masimo stock.
Bulls say / Bears say
Masimo agreed to sell its Sound United consumer audio business to HARMAN International for $350 million, enabling a strategic refocus on its core professional healthcare segment and freeing capital for innovation in patient monitoring technologies (Reuters).
A U.S. appeals court upheld two earlier ITC decisions favoring Masimo in its patent dispute with Apple over blood-oxygen sensing in smartwatches, reinforcing the company’s intellectual property protections and potential royalty leverage (Reuters).
Masimo’s proprietary SET® pulse-oximetry technology is used on over 200 million patients globally and serves as the primary pulse-oximetry solution at nine of the top ten U.S. hospitals ranked by U.S. News, underscoring its deep market penetration and clinical adoption (FT).
Masimo’s ongoing legal battles have intensified costs and uncertainty after the company sued U.S. Customs for reversing an import ban on Apple Watches featuring disputed pulse-oximetry technology, potentially undermining its ITC exclusion order and prolonging litigation expenses (Reuters).
In Q1 2025, Masimo recorded a GAAP loss from discontinued operations of $218 million—including a $295 million impairment on its consumer audio business—reflecting a significant write-down that weighed heavily on its consolidated results (FT).
A forthcoming U.S. Customs ruling on whether redesigned Apple Watches infringe Masimo’s pulse-oximetry patents threatens to allow Apple to import the contested devices, risking erosion of Masimo’s patent exclusivity and further legal reversals (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Masimo Financial Performance
Revenues and expenses
Masimo Earnings Performance
Company profitability
Masimo News
AllArticlesVideos
Masimo to Present in the Wells Fargo Healthcare Conference
Business Wire3 weeks ago
Masimo sues US Customs over approval of Apple Watch imports
Reuters4 weeks ago
Masimo O3® Regional Oximetry Receives FDA Clearance for Expanded Indication of Its Unique Delta Hemoglobin Parameters
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Masimo stock?
Masimo (MASI) has a market cap of $8B as of September 15, 2025.
What is the P/E ratio for Masimo stock?
The price to earnings (P/E) ratio for Masimo (MASI) stock is 0 as of September 15, 2025.
Does Masimo stock pay dividends?
No, Masimo (MASI) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Masimo dividend payment date?
Masimo (MASI) stock does not pay dividends to its shareholders.
What is the beta indicator for Masimo?
Masimo (MASI) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.